A new publication dated July 5, 2026 has appeared in the journal Theranostics, referencing semax. The paper is titled "Quantitative MRI Pharmacokinetic Modeling and MALDI Mass Spectrometry Imaging Biodistribution of a pH Mapping MRI Contrast Agent."
The publication is listed under PubMed identifier 42559144. It is categorized as a research publication rather than a clinical trial update or a recall notice.
No efficacy or safety outcomes are described here beyond the title of the work itself. The study focuses on quantitative MRI pharmacokinetic modeling and MALDI mass spectrometry imaging biodistribution related to a pH mapping MRI contrast agent.
Semax remains classified as an unapproved compound intended for research purposes only. This publication does not change that regulatory status. No dosing information, clinical indications, or outcome data are provided in the available event record.
Readers interested in the broader context of this compound, including its research classification and background, can consult the compound overview for additional information.